Clinical Trials Logo

Filter by:
NCT ID: NCT03434288 Completed - Diabetes Mellitus Clinical Trials

Assessment of PCR Multiplex Tests as a Tool to Obtain a Quicker Diagnosis of Bacteria Responsible for Foot Osteomyelitis Than Usual Cultures

RAPDIAGOS
Start date: February 8, 2018
Phase:
Study type: Observational

Bone samples from infected diabetic feet will be collected and tests will be performed for the diagnosis of causative bacteria. Samples will be processed by PCR multiplex tests and usual cultures for identification of causative bacteria and sensitivity to antibiotics. Results obtained by the two methods will be compared in terms of quickness and similarity of germ identification. Usual care strategy will not be modified since results of PCR multiplex tests will not be transmitted to the physicians before the results of usual cultures.

NCT ID: NCT03434184 Completed - Scoliosis Clinical Trials

Study of Walk in Patients With Pelvic Fixation

FBPM
Start date: October 12, 2018
Phase:
Study type: Observational

The purpose of this study is to determine the effect of double end spinal instrumentation from the upper thoracic to the pelvis with sacro-iliac fixation on the gait of ambulating patients with pelvic obliquity 6 month after surgery.

NCT ID: NCT03434015 Completed - Atrial Fibrillation Clinical Trials

Post-approval Study of Percutaneous Left Atrial Appendage Closure ( FLAAC-2 )

FLAAC-2
Start date: July 9, 2018
Phase:
Study type: Observational

Patients with atrial fibrillation are at significant risk of thrombus formation in the left atrial appendage, which can lead to a stroke or systemic embolism. This risk justifies first-line prescribing of long-term oral anticoagulant therapy in these patients. Percutaneous left atrial appendage closure, is a new interventional cardiology technique for patients at high risk of stroke related to atrial fibrillation in whom long term anticoagulation therapy cannot be conducted. This procedure involves implantation of an occlusion device into the left atrial appendage to close it and prevent migration of thrombotic material that can cause distant embolism. Closure of the left atrial appendage avoids long term prescription of anticoagulants while protecting patients against the risk of systemic embolism and stroke. In 2016, two devices developed for transcutaneous closure of the left atrial appendage (WATCHMAN, Boston Scientific, AMPLATZER CARDIAC PLUG, S. Jude Medical and its evolution AMPLATZER AMULET) were included in the list of products reimbursable in France. The French national authorities have requested the realization of a register whose objectives will be to evaluate: - The efficiency and safety of implanting devices in France - The type and duration of antithrombotic treatment prescribed after left atrial appendage closure

NCT ID: NCT03433989 Completed - Pregnancy Loss Clinical Trials

ACTRAMAT-D: Impact of Post-Traumatic Stress Disorder After Pregnancy Loss After 12 Weeks of Gestation

ACTRAMAT-D
Start date: March 7, 2018
Phase: N/A
Study type: Interventional

In France The prevalence of Pregnancy Loss after 12 weeks of gestation is around 3%. This situation is probably associated to a risk of post-traumatic stress disorder. As a part of the medical staff midwives are often confronted with this situation, however they can have difficulties to identify short and long term effects of a post-traumatic stress disorders. The purpose of the present study is to estimate and analyze the prevalence of short-term (1 month) post-traumatic stress disorder in women with pregnancy loss after 12 weeks of gestation.The symptoms of post-traumatic stress disorder will be tracked using the Impact of Event Scale-revisited and the Peritraumatic Dissociative Experiences Questionnaires.The diagnosis of post-traumatic stress disorder will also be clinically confirmed by a psychiatrist during a specific consultation.

NCT ID: NCT03433859 Completed - Hyperhidrosis Clinical Trials

Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)

SALUTOX
Start date: March 2016
Phase: Phase 3
Study type: Interventional

The aim of this study is to demonstrate onabotulinumtoxinA superiority to aluminium chloride for the treatment of residual limb hyperhidrosis.

NCT ID: NCT03433534 Completed - Lung Cancer Clinical Trials

Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer

NIVEAL
Start date: January 29, 2018
Phase:
Study type: Observational

To assess the relationship between progression free survival of patients treated with nivolumab for metastatic non small cell lung carcinoma or a metastatic renal cell carcinoma and nivolumab blood concentration. Collection of standard data prospectively.

NCT ID: NCT03433482 Completed - Clinical trials for Meningitis, Meningococcal

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

Start date: August 30, 2018
Phase: Phase 2
Study type: Interventional

MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries. The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY vaccine with the investigational MenACWY liquid vaccine aged for different lengths of time by storage at 2-8ºC.

NCT ID: NCT03432377 Completed - Clinical trials for Non Alcoholic Steatohepatitis

Coffee Consumption and NASH in the French Population.

COCANASH
Start date: November 15, 2017
Phase:
Study type: Observational

The aim of our study is to evaluate the effect of coffee consumption on the risk of severe liver fibrosis in French patients with NASH.

NCT ID: NCT03431857 Completed - Clinical trials for Rheumatoid Arthritis

Multi Centre Study on TESS V2 Shoulder System

Start date: October 20, 2010
Phase:
Study type: Observational

This study is a Post Market Clinical Follow-up study to fulfill the post market surveillance requirements. The data collected from this study will serve the purpose of confirming safety and performance of the TESS Shoulder System.

NCT ID: NCT03431805 Completed - Clinical trials for Postpartum Hemorrhage

TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery

TRAAP2
Start date: March 3, 2018
Phase: Phase 3
Study type: Interventional

The aim is to assess the impact of tranexamic acid (TXA) for preventing postpartum hemorrhage (PPH) following a cesarean section (CS).